| Literature DB >> 36066237 |
Laura Ruegsegger1, Jamie Xiao1, Arash Naziripour1, Trey Kanumuambidi1, Dylan Brown1, Felicia Williams2, Steven H Marshall3, Susan D Rudin3,4, Kelly Yen5, Tingyu Chu5, Liang Chen5, Emanuele Sozzi6, Luther Bartelt1, Barry Kreiswirth5, Robert A Bonomo3,4,7,8, David van Duin1.
Abstract
Patients with burn injuries are at high risk for infectious complications, and infections are the most common cause of death after the first 72 h of hospitalization. Hospital-acquired infections caused by multidrug resistant (MDR) Gram-negative bacteria (GNB) in this population are concerning. Here, we evaluated carriage with MDR GNB in patients in a large tertiary-care burn intensive care unit. Twenty-nine patients in the burn unit were screened for intestinal carriage. Samples were cultured on selective media. Median time from admission to the burn unit to first sample collection was 9 days (IQR 5 - 17 days). In 21 (72%) patients, MDR GNB were recovered; the most common bacterial species isolated was Pseudomonas aeruginosa, which was found in 11/29 (38%) of patients. Two of these patients later developed bloodstream infections with P. aeruginosa. Transmission of KPC-31-producing ST22 Citrobacter freundii was detected. Samples from two patients grew genetically similar C. freundii isolates that were resistant to ceftazidime-avibactam. On analysis of whole-genome sequencing, blaKPC-31 was part of a Tn4401b transposon that was present on two different plasmids in each C. freundii isolate. Plasmid curing experiments showed that removal of both copies of blaKPC-31 was required to restore susceptibility to ceftazidime-avibactam. In summary, MDR GNB colonization is common in burn patients and patient-to-patient transmission of highly resistant GNB occurs. These results emphasize the ongoing need for infection prevention and antimicrobial stewardship efforts in this highly vulnerable population.Entities:
Keywords: Citrobacter; Pseudomonas aeruginosa; burn; carbapenemase; ceftazidime-avibactam; hospital infections; plasmid-mediated resistance
Mesh:
Substances:
Year: 2022 PMID: 36066237 PMCID: PMC9487463 DOI: 10.1128/aac.00688-22
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.938